FARXIGA is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor proven to significantly reduce the risk of mortality in patients with CKD. 8-14 The DAPA-CKD Phase III trial showed that, on top ...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will showcase five real-world evidence (RWE) studies from its industry-leading Cardiovascular, Renal and Metabolism (CVRM) portfolio, reinforcing its ...
Farxiga (dapagliflozin) is a brand-name tablet that’s prescribed for different uses in adults with type 2 diabetes, heart failure, or kidney disease. Farxiga interacts with some other drugs and ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (AZN) today announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access ...
(RTTNews) - The US Food and Drug Administration AstraZeneca's Farxiga (dapagliflozin) to improve glycemic control in pediatric patients with type-2 diabetes or T2D aged 10 years and older. The FDA ...
The FDA’s Office of Prescription Drug Promotion issued an Untitled Letter, backdated to September 23, to Tracey M. Henderson, MS, MBA – AstraZeneca’s promotional regulatory affairs review director, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results